Mineralocorticoid Receptor Blockade in End-Stage Renal Disease

Mineralocorticoid Receptor Blockade in End-Stage Renal Disease Curr Hypertens Rep (2017) 19: 40 DOI 10.1007/s11906-017-0737-y ANTIHYPERTENSIVE AGENTS: MECHANISMS OF DRUG ACTION (M ERNST, SECTION EDITOR) 1 2,3 Radmila Lyubarova & Elvira O. Gosmanova Published online: 27 April 2017 Springer Science+Business Media New York 2017 Abstract consequence—were low with careful patient selection and Purpose of Review The purpose of this study was to summa- monitoring. rize recent findings about cardiovascular benefits and safety of . . aldosterone blockade in patients with end-stage renal disease Keywords End-stage renal disease Aldosterone (ESRD). Aldosterone blockade Mineralocorticoid receptor blockade Recent Findings It is now well recognized that aldosterone’s deleterious cardiovascular impact is not limited to its pressor effect arising from an increase in sodium reabsorption in the Introduction kidneys. Aldosterone has also been shown to increase blood pressure by a direct activation of the sympathetic nervous The paradigm describing the cardiovascular effects of aldoste- system, to cause endothelial and vascular smooth muscle cell rone is rapidly evolving. Historically, aldosterone was dysfunction, myocardial remodeling and fibrosis, and to have regarded as a mineralocorticoid hormone that is synthesized pro-arrhythmogenic actions in the heart. These unconvention- and released into the systemic circulation by the adrenal al extra-renal effects of aldosterone make its blockade feasible http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hypertension Reports Springer Journals

Mineralocorticoid Receptor Blockade in End-Stage Renal Disease

Loading next page...
 
/lp/springer_journal/mineralocorticoid-receptor-blockade-in-end-stage-renal-disease-Trv1tfaQiH
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media New York (outside the USA)
Subject
Medicine & Public Health; Internal Medicine; Cardiology; Metabolic Diseases; Nephrology; Primary Care Medicine; General Practice / Family Medicine
ISSN
1522-6417
eISSN
1534-3111
D.O.I.
10.1007/s11906-017-0737-y
Publisher site
See Article on Publisher Site

Abstract

Curr Hypertens Rep (2017) 19: 40 DOI 10.1007/s11906-017-0737-y ANTIHYPERTENSIVE AGENTS: MECHANISMS OF DRUG ACTION (M ERNST, SECTION EDITOR) 1 2,3 Radmila Lyubarova & Elvira O. Gosmanova Published online: 27 April 2017 Springer Science+Business Media New York 2017 Abstract consequence—were low with careful patient selection and Purpose of Review The purpose of this study was to summa- monitoring. rize recent findings about cardiovascular benefits and safety of . . aldosterone blockade in patients with end-stage renal disease Keywords End-stage renal disease Aldosterone (ESRD). Aldosterone blockade Mineralocorticoid receptor blockade Recent Findings It is now well recognized that aldosterone’s deleterious cardiovascular impact is not limited to its pressor effect arising from an increase in sodium reabsorption in the Introduction kidneys. Aldosterone has also been shown to increase blood pressure by a direct activation of the sympathetic nervous The paradigm describing the cardiovascular effects of aldoste- system, to cause endothelial and vascular smooth muscle cell rone is rapidly evolving. Historically, aldosterone was dysfunction, myocardial remodeling and fibrosis, and to have regarded as a mineralocorticoid hormone that is synthesized pro-arrhythmogenic actions in the heart. These unconvention- and released into the systemic circulation by the adrenal al extra-renal effects of aldosterone make its blockade feasible

Journal

Current Hypertension ReportsSpringer Journals

Published: Apr 27, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off